Research ExplorerPublicationsHOXB13 overexpression is an independent predictor of early P...

HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy

Standard

HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy. / Zabalza, Cristina Villares; Adam, Meike; Burdelski, Christoph; Wilczak, Waldemar; Wittmer, Corinna; Kraft, Stefan; Krech, Till; Steurer, Stefan; Koop, Christina; Hube-Magg, Claudia; Graefen, Markus; Heinzer, Hans; Minner, Sarah; Simon, Ronald; Sauter, Guido; Schlomm, Thorsten; Tsourlakis, Maria Christina.

In: ONCOTARGET, Vol. 6, No. 14, 23.03.2015, p. 12822-12834.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Zabalza, CV, Adam, M, Burdelski, C, Wilczak, W, Wittmer, C, Kraft, S, Krech, T, Steurer, S, Koop, C, Hube-Magg, C, Graefen, M, Heinzer, H, Minner, S, Simon, R, Sauter, G, Schlomm, T & Tsourlakis, MC 2015, 'HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy', ONCOTARGET, vol. 6, no. 14, pp. 12822-12834.

APA

Zabalza, C. V., Adam, M., Burdelski, C., Wilczak, W., Wittmer, C., Kraft, S., Krech, T., Steurer, S., Koop, C., Hube-Magg, C., Graefen, M., Heinzer, H., Minner, S., Simon, R., Sauter, G., Schlomm, T., & Tsourlakis, M. C. (2015). HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy. ONCOTARGET, 6(14), 12822-12834.

Vancouver

Zabalza CV, Adam M, Burdelski C, Wilczak W, Wittmer C, Kraft S et al. HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy. ONCOTARGET. 2015 Mar 23;6(14):12822-12834.

Bibtex

@article{406fba6bbdf543f2adfd4f72b049e8c5,
title = "HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy",
abstract = "HOXB13 is a prostate cancer susceptibility gene which shows a cancer predisposing (G84E) mutation in 0.1-0.6% of males. We analyzed the prognostic impact of HOXB13 expression by immunohistochemistry on a tissue microarray containing more than 12,400 prostate cancers. Results were compared to tumor phenotype, biochemical recurrence, androgen receptor (AR) and prostate specific antigen (PSA) as well as molecular subtypes defined by ERG status and genomic deletions of 3p, 5q, 6q, and PTEN. HOXB13 immunostaining was detectable in 51.7% of 10,216 interpretable cancers and considered strong in 9.6%, moderate in 19.7% and weak in 22.3% of cases. HOXB13 expression was linked to advanced pT stage, high Gleason grade, positive lymph node status (p < 0.0001 each), high pre-operative PSA levels (p = 0.01), TMPRSS2:ERG fusion, PTEN deletions, AR expression, cell proliferation, reduced PSA expression and early PSA recurrence (p < 0.0001 each). The prognostic value of HOXB13 was independent from established parameters including Gleason, stage, nodal stage and PSA. Co-expression analysis identified a subset of tumors with high HOXB13 and AR but low PSA expression that had a particularly poor prognosis. HOXB13 appears to be a promising candidate for clinical routine tests either alone or in combination with other markers, including AR and PSA.",
author = "Zabalza, {Cristina Villares} and Meike Adam and Christoph Burdelski and Waldemar Wilczak and Corinna Wittmer and Stefan Kraft and Till Krech and Stefan Steurer and Christina Koop and Claudia Hube-Magg and Markus Graefen and Hans Heinzer and Sarah Minner and Ronald Simon and Guido Sauter and Thorsten Schlomm and Tsourlakis, {Maria Christina}",
year = "2015",
month = mar,
day = "23",
language = "English",
volume = "6",
pages = "12822--12834",
journal = "ONCOTARGET",
issn = "1949-2553",
publisher = "IMPACT JOURNALS LLC",
number = "14",

}

RIS

TY - JOUR

T1 - HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy

AU - Zabalza, Cristina Villares

AU - Adam, Meike

AU - Burdelski, Christoph

AU - Wilczak, Waldemar

AU - Wittmer, Corinna

AU - Kraft, Stefan

AU - Krech, Till

AU - Steurer, Stefan

AU - Koop, Christina

AU - Hube-Magg, Claudia

AU - Graefen, Markus

AU - Heinzer, Hans

AU - Minner, Sarah

AU - Simon, Ronald

AU - Sauter, Guido

AU - Schlomm, Thorsten

AU - Tsourlakis, Maria Christina

PY - 2015/3/23

Y1 - 2015/3/23

N2 - HOXB13 is a prostate cancer susceptibility gene which shows a cancer predisposing (G84E) mutation in 0.1-0.6% of males. We analyzed the prognostic impact of HOXB13 expression by immunohistochemistry on a tissue microarray containing more than 12,400 prostate cancers. Results were compared to tumor phenotype, biochemical recurrence, androgen receptor (AR) and prostate specific antigen (PSA) as well as molecular subtypes defined by ERG status and genomic deletions of 3p, 5q, 6q, and PTEN. HOXB13 immunostaining was detectable in 51.7% of 10,216 interpretable cancers and considered strong in 9.6%, moderate in 19.7% and weak in 22.3% of cases. HOXB13 expression was linked to advanced pT stage, high Gleason grade, positive lymph node status (p < 0.0001 each), high pre-operative PSA levels (p = 0.01), TMPRSS2:ERG fusion, PTEN deletions, AR expression, cell proliferation, reduced PSA expression and early PSA recurrence (p < 0.0001 each). The prognostic value of HOXB13 was independent from established parameters including Gleason, stage, nodal stage and PSA. Co-expression analysis identified a subset of tumors with high HOXB13 and AR but low PSA expression that had a particularly poor prognosis. HOXB13 appears to be a promising candidate for clinical routine tests either alone or in combination with other markers, including AR and PSA.

AB - HOXB13 is a prostate cancer susceptibility gene which shows a cancer predisposing (G84E) mutation in 0.1-0.6% of males. We analyzed the prognostic impact of HOXB13 expression by immunohistochemistry on a tissue microarray containing more than 12,400 prostate cancers. Results were compared to tumor phenotype, biochemical recurrence, androgen receptor (AR) and prostate specific antigen (PSA) as well as molecular subtypes defined by ERG status and genomic deletions of 3p, 5q, 6q, and PTEN. HOXB13 immunostaining was detectable in 51.7% of 10,216 interpretable cancers and considered strong in 9.6%, moderate in 19.7% and weak in 22.3% of cases. HOXB13 expression was linked to advanced pT stage, high Gleason grade, positive lymph node status (p < 0.0001 each), high pre-operative PSA levels (p = 0.01), TMPRSS2:ERG fusion, PTEN deletions, AR expression, cell proliferation, reduced PSA expression and early PSA recurrence (p < 0.0001 each). The prognostic value of HOXB13 was independent from established parameters including Gleason, stage, nodal stage and PSA. Co-expression analysis identified a subset of tumors with high HOXB13 and AR but low PSA expression that had a particularly poor prognosis. HOXB13 appears to be a promising candidate for clinical routine tests either alone or in combination with other markers, including AR and PSA.

M3 - SCORING: Journal article

C2 - 25825985

VL - 6

SP - 12822

EP - 12834

JO - ONCOTARGET

JF - ONCOTARGET

SN - 1949-2553

IS - 14

ER -